By Fineline Cube 
GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China’s National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients whose disease remains inadequately controlled despite systemic corticosteroids and/or surgery. This marks the second NMPA approval for the ultra-long-acting biologic within weeks, following its late-March approval for severe eosinophilic asthma.
Regulatory Timeline & Indications
| Parameter | Detail |
|---|---|
| Company | GlaxoSmithKline plc (GSK, NYSE: GSK) |
| Product | Exdensur (depemokimab) |
| Mechanism | Ultra-long-acting interleukin-5 (IL-5) inhibitor |
| First China Approval | Late March 2026 – Severe eosinophilic asthma (adults/adolescents ≥12 years) |
| Second Approval | April 2026 – CRSwNP (adults inadequately controlled by steroids/surgery) |
| Dosing Regimen | Twice-yearly subcutaneous administration |
| Key Differentiator | First ultra-long-acting biologic specifically developed for type 2 inflammation-driven respiratory diseases |
Clinical Profile & Mechanism of Action
- Molecular Innovation: Exdensur combines high affinity and high binding potency for interleukin-5 (IL-5) with an extended half-life, enabling unprecedented twice-yearly dosing frequency
- Target Population: Adult CRSwNP patients who have failed to achieve adequate disease control with conventional therapies including systemic corticosteroids and surgical intervention
- Therapeutic Approach: Administered as add-on therapy combined with intranasal corticosteroids
- Type 2 Inflammation Focus: Specifically engineered for diseases driven by eosinophilic inflammation pathways
Commercial Strategy & Market Opportunity
Dual-Indication Portfolio Approach
- Severe Eosinophilic Asthma: Approved late March 2026 for maintenance treatment in adults and adolescents aged 12+
- CRSwNP Expansion: April 2026 approval creates cross-indication prescribing opportunities for pulmonologists and ENT specialists
- Shared Pathophysiology: Both indications target IL-5-driven eosinophilic inflammation, enabling unified clinical messaging
China Market Dynamics
- CRSwNP Prevalence: Estimated 2-4% adult prevalence in China, representing 28-56 million potential patients
- Treatment Gap: Significant unmet need among patients refractory to steroids and surgery
- Pricing Premium: Ultra-long-acting profile supports premium pricing versus existing biologics requiring monthly or bi-monthly dosing
- Reimbursement Strategy: GSK expected to pursue NRDL inclusion for both indications in 2027 negotiations
Competitive Landscape
- Differentiation: Twice-yearly dosing represents significant advantage over competitors requiring more frequent administration
- First-Mover Advantage: First ultra-long-acting biologic specifically developed for type 2 respiratory inflammation in China
- Portfolio Synergy: Complements GSK’s broader respiratory franchise including Trelegy and Nucala
Strategic Implications
- Rapid Regulatory Success: Two NMPA approvals within weeks demonstrates GSK’s regulatory execution capability in China’s evolving biologics landscape
- Type 2 Inflammation Leadership: Positions GSK as a comprehensive provider across the spectrum of IL-5-driven respiratory diseases
- Dosing Innovation: Extended half-life technology may set new standard for biologic convenience in chronic respiratory conditions
- Revenue Trajectory: Dual indications could accelerate China revenue ramp, with analysts projecting peak sales of $300-500M annually by 2030
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations. Actual results may differ due to risks including reimbursement decisions, competitive dynamics, and market adoption rates.-Fineline Info & Tech